StonvexLoading…
StonvexStonvexStonvexCore line items from CLS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $4.05B | $12.39B | $8.74B | $5.54B |
Operating Income | $272.10M | $1.04B | $726.30M | $401.30M |
Net Income | $212.30M | $832.50M | $565.00M | $297.20M |
EPS (Diluted) | $1.83 | $7.16 | $4.86 | $2.55 |
Total Assets | $8.26B | $7.21B | $6.61B | $6.24B |
Total Liabilities | $6.16B | $5.00B | $4.58B | $4.48B |
Cash & Equivalents | $378.00M | $595.60M | $305.90M | $313.80M |
Free Cash Flow OCF − CapEx | $126.80M | $458.30M | $302.40M | $213.50M |
Shares Outstanding | 115.70M | 114.91M | 116.20M | 116.40M |